CL2014001602A1 - Formulacion en suspension que incluye al menos un antibiotico de cefalosporina o una sal del mismo, un aceite y un disolvente de acetato de glicerol; metodo de preparacion; y su uso para tratar o prevenir una infeccion bacteriana. - Google Patents

Formulacion en suspension que incluye al menos un antibiotico de cefalosporina o una sal del mismo, un aceite y un disolvente de acetato de glicerol; metodo de preparacion; y su uso para tratar o prevenir una infeccion bacteriana.

Info

Publication number
CL2014001602A1
CL2014001602A1 CL2014001602A CL2014001602A CL2014001602A1 CL 2014001602 A1 CL2014001602 A1 CL 2014001602A1 CL 2014001602 A CL2014001602 A CL 2014001602A CL 2014001602 A CL2014001602 A CL 2014001602A CL 2014001602 A1 CL2014001602 A1 CL 2014001602A1
Authority
CL
Chile
Prior art keywords
treat
salt
oil
preparation
prevent
Prior art date
Application number
CL2014001602A
Other languages
English (en)
Inventor
Alawi Fadil Al
Karthigeyan Nanjan
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of CL2014001602A1 publication Critical patent/CL2014001602A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068Rumen, e.g. rumen bolus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2014001602A 2011-12-23 2014-06-18 Formulacion en suspension que incluye al menos un antibiotico de cefalosporina o una sal del mismo, un aceite y un disolvente de acetato de glicerol; metodo de preparacion; y su uso para tratar o prevenir una infeccion bacteriana. CL2014001602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ59738911 2011-12-23

Publications (1)

Publication Number Publication Date
CL2014001602A1 true CL2014001602A1 (es) 2014-10-24

Family

ID=48668892

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001602A CL2014001602A1 (es) 2011-12-23 2014-06-18 Formulacion en suspension que incluye al menos un antibiotico de cefalosporina o una sal del mismo, un aceite y un disolvente de acetato de glicerol; metodo de preparacion; y su uso para tratar o prevenir una infeccion bacteriana.

Country Status (15)

Country Link
KR (1) KR20140102319A (es)
CN (1) CN104080456A (es)
AU (1) AU2012359296B2 (es)
BR (1) BR112014014786A2 (es)
CL (1) CL2014001602A1 (es)
CO (1) CO7101241A2 (es)
CR (1) CR20140355A (es)
DO (1) DOP2014000146A (es)
IL (1) IL233299A0 (es)
MX (1) MX2014007735A (es)
MY (1) MY167596A (es)
NI (1) NI201400064A (es)
PE (1) PE20142373A1 (es)
PH (1) PH12014501384A1 (es)
WO (1) WO2013095166A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102113822B1 (ko) 2012-07-17 2020-05-22 바이엘 뉴질랜드 리미티드 주사용 항생제 제제 및 그의 이용 방법
US9452155B2 (en) 2012-07-17 2016-09-27 Bayer New Zealand Ltd Injectable antibiotic formulations and their methods of use
CA3132159C (en) 2019-03-06 2023-11-21 Zoetis Services Llc A ready-to-use injectable formulation comprising cefovecin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614465B2 (en) * 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
WO2009032843A2 (en) * 2007-09-06 2009-03-12 Auspex Pharmaceuticals, Inc. Deuterated ethambutols and their use
CN101401787B (zh) * 2008-11-19 2011-05-18 肖希龙 一种头孢噻呋长效注射液及其制备方法
CN101953889B (zh) * 2010-09-07 2013-04-10 西北农林科技大学 一种复方头孢噻呋混悬乳剂注射液及其制备方法

Also Published As

Publication number Publication date
PE20142373A1 (es) 2015-02-11
WO2013095166A1 (en) 2013-06-27
PH12014501384A1 (en) 2014-09-22
IL233299A0 (en) 2014-08-31
CR20140355A (es) 2014-10-29
AU2012359296B2 (en) 2014-12-11
BR112014014786A2 (pt) 2017-06-13
CN104080456A (zh) 2014-10-01
DOP2014000146A (es) 2014-07-31
CO7101241A2 (es) 2014-10-31
NI201400064A (es) 2014-11-28
MX2014007735A (es) 2014-08-01
MY167596A (en) 2018-09-20
KR20140102319A (ko) 2014-08-21
AU2012359296A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
CL2015001084A1 (es) Compuestos derivados de cefem 2-sustituidos; composicion farmaceutica que los comprende; utiles como agentes efectivos contra bacterias gram negativas que producen beta-lactamasa, incluyendo bacterias resistentes a multiples farmacos, y/o bacterias gram positivas.
CL2014003035A1 (es) Compuestos derivados de diazabiciclooctano, inhibidores de beta-lactamasa; composicion farmaceutica que los comprende; proceso para prepararlos; y metodo para tratar una infeccion bacteriana.
CL2014002589A1 (es) Compuestos inhibidores de beta-lactamasas derivados de 7-oxo-1,6-diazabiciclo[3.2.1] octano; composicion farmaceutica que los comprende y uso para tratar una infeccion bacteriana.
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
BR112015009636A8 (pt) composto, métodos para o tratamento de um hospedeiro infectado, métodos para a prevenção de uma infecção, métodos para a redução da atividade biológica de uma infecção e uso de um composto
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112013030520A2 (pt) método, sistema, e, composição.
WO2012116010A3 (en) Antibiotic tolerance inhibitors
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
CL2014002904A1 (es) Una composición geopolimérica de aluminosilicato; metodo de preparacion.
BR112016011830A2 (pt) composições bacterianas sinergísticas e métodos para produção e uso das mesmas.
EP3003322A4 (en) Compounds and methods for treating bacterial infections
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
EP2947084B8 (en) Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
BR112015000534A2 (pt) método para a preparação de 2,4-dihidroxibutirato, microrganismo, organismo e uso
BR112014031412A2 (pt) método de preparação de uma composição, composição e seu uso, e kit.
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112016013509A2 (pt) “sistema para a administração de inoculantes microbianos e materiais e métodos relacionados”.
BR112015002755A2 (pt) derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
WO2012097185A3 (en) Omv vaccine against burkholderia infections
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
CL2016002873A1 (es) Composición farmacéutica para reducir el daño talámico.